MedPath

Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Phase 2
Conditions
Kidney Cancer
Registration Number
NCT00024388
Lead Sponsor
Theradex
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.

Detailed Description

OBJECTIVES: I. Determine the tumor response rate, duration of response, and time to disease progression in patients with locally advanced, metastatic, or unresectable renal cell cancer treated with DHA-paclitaxel. II. Determine the overall survival of patients treated with this drug. III. Determine the toxicity profile of this drug in these patients. IV. Assess the quality of life of patients treated with this drug.

OUTLINE: This is a multicenter study. Patients receive DHA-paclitaxel IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, every 2 courses, and at completion of treatment. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (7)

Jonsson Comprehensive Cancer Center, UCLA

🇺🇸

Los Angeles, California, United States

Louisiana State University Health Sciences Center - Shreveport

🇺🇸

Shreveport, Louisiana, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

🇺🇸

Baltimore, Maryland, United States

Cleveland Clinic Taussig Cancer Center

🇺🇸

Cleveland, Ohio, United States

Lucille Parker Markey Cancer Center, University of Kentucky

🇺🇸

Lexington, Kentucky, United States

Arizona Oncology Associates

🇺🇸

Tucson, Arizona, United States

Herbert Irving Comprehensive Cancer Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath